Author

E. Caserta

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

F. Pichiorri· 3 shared A. Chowdhury· 2 shared A. Krishnan· 2 shared G. Marcucci· 2 shared J. Shively· 2 shared L. Ghoda· 2 shared X. Wang· 2 shared A. A. Dona· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

F. Pichiorri

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers

M. Kuznetsov, V. Adhikarla, E. Caserta, X. Wang, J. Shively, F. Pichiorri, R. C. Rockne

This paper develops a mathematical model to optimize targeted radionuclide therapy for multiple myeloma by identifying key principles for improving treatment efficacy while minimizing toxicity.

bioRxiv · May 22, 2024Cancer Biology

Leveraging IFNγ/CD38 regulation to unmask and target leukemia stem cells in acute myelogenous leukemia

M. Murtadha, M. Park, Y. Zhu, E. Caserta, A. A. Dona, M. Singer, H. Vahed, T. Tandoh, A. Gonzalez, K. Ly, J. Sanchez, A. Chowdhury, A. Pozhitkov, L. Ghoda, L. Li, , F. Pichiorri

This paper develops a T cell engager that uses IFNγ to upregulate CD38 on leukemia stem cells, enabling their targeting and depletion in AML.

bioRxiv · Feb 27, 2023 · PreprintCancer Biology

Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting

D. Viola, A. Dona, E. Caserta, E. Troadec, E. G. Gunes, F. Besi, T. McDonald, L. Ghoda, J. F. Sanchez, J. Khalife, M. Martella, C. Karanes, M. Htut, X. Wang, M. Rosenzweig, , F. Pichiorri

This study shows that daratumumab targets CD38+ NK cells to induce immune activation and anti-myeloma activity despite reducing total NK cell frequency.

bioRxiv · Nov 22, 2019Cancer Biology